Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973167 | 0.90 | ESR1 (0.43) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1974100 | 0.89 | ESR1 (0.43) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1973059 | 0.88 | ESR1 (0.44) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1974203 | 0.88 | L3MBTL1 (0.45) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1973669 | 0.85 | ESR1 (0.41) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1974155 | 0.85 | ESR1 (0.39) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1973776 | 0.85 | EGFR (0.45) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1974634 | 0.84 | ESR1 (0.43) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1976187 | 0.83 | ESR1 (0.39) | ESR1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL1974246 | 0.83 | CDC7 (0.39) | ESR1TSHRLMNACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000006-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8703795-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1866318-B1 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN INC (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1866318-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094292-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | ESR1 3632/4885TSHR 2835/4885LMNA 4317/4885 |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | HIF1AN, HIF1A, EGLN2 | ESR1 3632/4885TSHR 2835/4885LMNA 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.